Group 2A: HR+ Breast Cancer; Drug Resistance; Predictive Biomarkers

Poster #P2-03-10: DNA replication licensing is associated with resistance to CDK4/6 inhibitors in ER-positive breast cancer

Poster #P1-13-07: Investigating NF1 mutations in circulating tumor DNA of patients with hormone-receptor positive (HR+) breast tumors resistant to CDK4/6 inhibition (CDK4/6i): A retrospective clinical analysis